MINT-IRBESARTAN/HCTZ TABLET

Land: Kanada

Sprache: Englisch

Quelle: Health Canada

Wirkstoff:

IRBESARTAN; HYDROCHLOROTHIAZIDE

Verfügbar ab:

MINT PHARMACEUTICALS INC

ATC-Code:

C09DA04

INN (Internationale Bezeichnung):

IRBESARTAN AND DIURETICS

Dosierung:

300MG; 25MG

Darreichungsform:

TABLET

Zusammensetzung:

IRBESARTAN 300MG; HYDROCHLOROTHIAZIDE 25MG

Verabreichungsweg:

ORAL

Einheiten im Paket:

30/100/1000

Verschreibungstyp:

Prescription

Therapiebereich:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

Produktbesonderheiten:

Active ingredient group (AIG) number: 0240086003; AHFS:

Berechtigungsstatus:

CANCELLED POST MARKET

Berechtigungsdatum:

2020-07-08

Fachinformation

PRODUCT MONOGRAPH
Pr
MINT-IRBESARTAN/HCTZ
(Irbesartan and hydrochlorothiazide Tablets)
150/12.5 mg, 300/12.5 mg and 300/25 mg Tablets
House Standard
Angiotensin II AT
1
Receptor Blocker / Diuretic
Mint Pharmaceuticals Inc.
Date of Revision:
1093 Meyerside Drive, Unit 1
August 26, 2019
Mississauga, Ontario
L5T 1J6
CONTROL NO.: 230635
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.............................................................. 3
SUMMARY PRODUCT INFORMATION
.....................................................................................
3
INDICATIONS AND CLINICAL USE
..........................................................................................
3
CONTRAINDICATIONS
................................................................................................................
4
WARNINGS AND PRECAUTIONS
..............................................................................................
4
ADVERSE REACTIONS
................................................................................................................
9
DRUG INTERACTIONS
...............................................................................................................
14
DOSAGE AND ADMINISTRATION
...........................................................................................
20
OVERDOSAGE
.............................................................................................................................
22
ACTION AND CLINICAL PHARMACOLOGY
.........................................................................
22
STORAGE AND STABILITY
......................................................................................................
26
DOSAGE FORMS, COMPOSITION AND PACKAGING
.......................................................... 26
PART II: SCIENTIFIC INFORMATION
....................................................................................
27
PHARMACEUTICAL INFORMATION
...............................................................................